返回 A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Attends 28th GW-ICC

[2017-11-24] 

Beijing, China – From October 12 to October 15, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") attended the 28th Great Wall International Congress of Cardiology ("GW-ICC") held in Beijing and hosted a case competition in which industry experts were invited to exchange ideas on the treatment of cardiovascular diseases. In adherence to the principle of "Public welfare, Prevention, Norm, Innovation" and the theme of "Return to the humanities, Return to the clinical, Return to basic skills", GW-ICC has been going on for 27 years and has become an internationally renowned cardiology congress that contains cardiovascular diseases from basic to clinical, integrates related disciplines and covers Asia Pacific and global audience.
 
On October 13, MicroPort® hosted a case competition. Director Lijun Guo of Peking University Third Hospital, Director Jinghua Liu of Beijing Anzhen Hospital of Capital Medical University, Director Changqian Wang of Shanghai Ninth People's Hospital, and Director Yan Huang of Gansu Provincial Hospital were invited as guest speakers to review the cases. After fierce competition, the case of double branch CTO by Bo Xiong of the Third People's Hospital of Chengdu, the case of complex lesion and complications by Wenquan Zhang of Shanghai Putuo District Central Hospital, and the case of left main bifurcation lesion by Jiankang Meng of the Second Hospital of Hebei Medical University won the third place since the treatments successfully saved the patients' life and improved their life quality. The case of right coronary CTO by Director Yunqing Chen of the Second Affiliated Hospital of Chongqing Medical University won the second place for its argument about culprit vessel patency. The case of CTO treatment with Hybrid technique by Chenggang Zhu of Fuwai Hospital of Chinese Academy of Medical Sciences took the crown for it showed excellent technique and recorded complete process of the operation. The venue was fully packed and the presentations were well received by the attendees, who also had active interaction with the speakers. Since 2016, MicroPort® hosted the case competition in various national-level congresses such as South China International Congress of Cardiology, China Cardiovascular Interventional Forum, and Cardiac Imaging & Cardiac Interventional Summit, to build an academic platform for experts of interventional treatment to discuss and share complex or typical cases, which has received positive feedback from many experts in the cardiology field.
 
During the meeting, MicroPort® R&D staff also interviewed several experts regarding the clinical performance of Firefighter® PTCA Balloon Catheter ("Firefighter®") and other coronary stents. Professor Zheng Zhang of the First Hospital of Lanzhou University spoke highly of Firefighter®, saying "it is one of the best balloons in the world." Professor Bo Luan of Liaoning Provincial People's Hospital highly spoke of the crossability, pushability, and traceability of Firefighter® according to his personal clinical experience. Professor Qingsheng Wang of First Hospital of Qinhuangdao and Professor Qiming Wu of Ditan Hospital of Capital Medical University said they are looking forward to the introduction of Firefighter® to their hospitals to benefit more patients. Director Haiyan Wang of Tangdu Hospital and Director Jianjun Jiang of Taizhou Hospital of Zhejiang Province also recognized the performance of MicroPort®'s stent and balloon products, and offered pervious suggestions on further improvement.
 
Lei Jiang, MicroPort® First Vice President of Domestic Coronary Sales & Marketing, said: " We arranged such kind of academic events with the hope of showcasing the excellent performance of our coronary products while enhancing the communication with physicians to keep improving our products based on their clinical needs, and thereby promote the development of treatment technology in China's interventional cardiology and benefit more domestic patients."

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:MicroPort® Hosts Firehawk® SAFE Study Protocol Symposium
[Next]:MicroPort® Endovascular Hosts Product Launch of Castor®